Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Declines By 33.8%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 91,700 shares, a decline of 33.8% from the November 30th total of 138,600 shares. Based on an average daily volume of 2,921,900 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, the company has an average rating of “Hold”.

Bayer Aktiengesellschaft Stock Up 2.5 %

Shares of Bayer Aktiengesellschaft stock opened at $4.97 on Monday. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $9.79. The stock has a market cap of $19.53 billion, a price-to-earnings ratio of -19.12 and a beta of 1.03. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19. The company has a fifty day moving average price of $5.66 and a 200 day moving average price of $6.84.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10). The company had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.